Lilly’s quarterly results Thursday, combined with Novo Nordisk’s unsolicited offer for a startup, confirm the $72 billion ...
Zacks.com on MSN
LLY's Oral GLP-1 Pill Scores Another Pair of Diabetes Wins
Eli Lilly's oral GLP-1 pill orforglipron delivers strong A1C reductions in two late-stage diabetes studies, reinforcing its 2026 filing plans.
Pharmaceutical company Novo Nordisk is working on an Ozempic-style semaglutide tablet just for weight loss, and early results ...
Novo Nordisk (NYSE:NVO) just got another big win in the U.S. The FDA has cleared its oral GLP-1 pill, Rybelsus, to help ...
First there were Victoza and Saxenda, then Ozempic seized the spotlight - followed by Wegovy and Mounjaro. And ever-better products have been promised soon.
Eli Lilly raised its full-year profit and revenue forecast on Thursday as strong appetite for its widely popular weight-loss ...
Eli Lilly's experimental weight-loss pill, orforglipron, has met key FDA criteria for an expedited review, boosting its ...
Eli Lilly ( NYSE: LLY) said in April that its oral weight loss therapy, orforglipron, reached the main goals in a third Phase ...
Eli Lilly hiked its outlook as sales soared for its popular weight-loss drugs Zepbound and Mounjaro. The company also recently announced a partnership with Walmart that will expand access to Zepbound ...
U.S. sales of Lilly’s weight-loss treatment Zepbound nearly tripled, to $3.57 billion, in the third quarter. Meanwhile, ...
Eli Lilly & Co. has already produced billions of doses of its next-generation weight-loss pill, anticipating massive global ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback